With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.388109-26-0,Ethyl 3-oxotetrahydro-2H-pyran-4-carboxylate,as a common compound, the synthetic route is as follows.
To a solution of ethyl 3-oxotetrahydro-2H-pyran-4-carboxylate (4.40 g, 25.50 mmol) and DIEA (13.21 ml, 76.66 mmol) in 120 ml of DCM at 0 C was added triflic anhydride (4.62 ml, 28.11 mmol) and the mixture was allowed to stir overnight at room temperature. DCM was removed under vacuum and the residue dissolved in EtOAc and washed with 1 N HCI and then brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified on a silica gel column eluting with 20% EtOAc/heptane to yield ethyl 5-(((trifluoromethyl)sulfonyl)oxy)-3,6-dihydro-2H- pyran-4-carboxylate as a light brown oil. Mass spectrum (ESI, m/z): Calculated for C9H11F3O6S, 305.2 (M+H), Measured 305.0.
388109-26-0, 388109-26-0 Ethyl 3-oxotetrahydro-2H-pyran-4-carboxylate 21362493, aTetrahydropyrans compound, is more and more widely used in various fields.
Reference£º
Patent; JANSSEN PHARMACEUTICA NV; LANTER, James C.; WALL, Mark; SUI, Zhihua; (0 pag.)WO2019/171278; (2019); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics